Search

Displaying results 3561 - 3570 of 4236 in total
  1. Drug

    ZYC300

    go.drugbank.com/drugs/DB04986
    Investigational

    It is designed as a vaccine, intended to increase immune system sensitivity to CYP1B1, an enzyme highly prevalent in tumor cells.

  2. Drug

    Tanespimycin

    go.drugbank.com/drugs/DB05134
    Investigational

    Tanespimycin, manufactured by Conforma Therapeutics is under development as a small molecule inhibitor of heat shock protein 90 (HSP90).

  3. Drug

    D-threo-neopterin

    go.drugbank.com/drugs/DB02385
    Experimental

    (From Stedman, 26th ed) Neopterin also serves as a precursor in the biosynthesis of biopterin.

  4. Drug

    Tiletamine

    go.drugbank.com/drugs/DB11549
    ExperimentalVet approved

    Tiletamine hydrochloride, the salt form, exists as odorless white crystals.

  5. Drug

    PZM21

    go.drugbank.com/drugs/DB14030
    Experimental

    novel μ-opioid receptor (MOPr) ligand that has been reported to induce minimal arrestin recruitment and be devoid of the respiratory depressant effects characteristic of classical μ-opioid ligands such as

  6. Drug

    ABBV-514

    go.drugbank.com/drugs/DB17586
    Investigational

    ABBV-514 is in development for the treatment of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) as a single agent and in combination with a PD-1 inhibitor.[L45464]

  7. Drug

    Erythromycin

    go.drugbank.com/drugs/DB00199
    ApprovedInvestigationalVet approved

    Erythromycin is a bacteriostatic antibiotic drug produced by a strain of Saccharopolyspora erythraea (formerly Streptomyces erythraeus) and belongs to the macrolide group of antibiotics which consists of Azithromycin, Clarithromycin, Spi...

  8. Drug

    Gadopiclenol

    go.drugbank.com/drugs/DB17084
    ApprovedInvestigational

    However, studies revealed that NSF was associated with linear GBCAs, not macrocyclic GBCAs, such as gadopiclenol.

  9. Drug

    Navepegritide

    go.drugbank.com/drugs/DB17824
    ApprovedInvestigational

    [L56065] Navepegritide was approved by the US FDA in February 2026 for use in patients 2 years of age and older with achondroplasia with open epiphyses.[L56058,L56065]

  10. Drug

    Rolapitant

    go.drugbank.com/drugs/DB09291
    ApprovedInvestigational

    Neurokinin-1 is also known as Tachykinin Receptor 1 (TACR1), Neurokinin 1 Receptor (NK1R), and Substance P Receptor (SPR).